Commercial intelligence you can defend in the room.

The difference

Not prose about the market — decisions your team can act on.

A syndicated report describes the market. An AXLRx brief frames the decisions your launch team has to make on positioning, on access, and on where to compete. Every section answers a named commercial question, scoped to your asset and proposed label, not the category in aggregate.

And every figure is verified against a live source at the point of writing. If it can't be sourced, it doesn't appear.

Four things hold across every brief: evidence-backed, built on consulting methodology, reviewed by a practising consultant, and delivered decision-ready — not a data dump you still have to interpret.

The standard: verify or drop.

Every figure clears these checks before delivery.

1. 01Live citationEvery claim is cited to a live PMID, ClinicalTrials.gov ID or URL at the point of writing. Uncited claims are dropped, not estimated.
2. 02Live metadataPubMed metadata is fetched live during authoring. Model memory mis-attributes authors and journals even on correct identifiers.
3. 03Numeric cross-checkThe figure must appear in the cited source, not merely be consistent with it. An independent audit pass then re-checks every link before delivery.

A fourth check, after the first three: every brief is read by a pharma commercial consultant before it ships, not released straight from a model.

Three steps. No retainer.

1. 01Submit your assetDrug, mechanism, indication, target cohort, geography — five minutes.
2. 02Scope confirmed in 24hWe confirm scope, clarify open questions and lock the delivery window.
3. 03Delivered in 72hA decision-structured PDF, an editable Excel model and an optional deck — with a readout call.

Tell us your asset.

Your team has the brief in 72 hours. Scope confirmation takes one call.